
|Videos|January 16, 2014
The Immunogenic Potential of Biosimilars: Should Health Care Providers Be Concerned?
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
Advertisement
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
3
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
4
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
5








































































































































